AB Science
AB
Company Profile
Business description
AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing of protein kinase inhibitors. It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine.
Contact
3, Avenue George V
Paris75008
FRAT: +33 147200014
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
39
Stocks News & Analysis
stocks
ResMed earnings: Solid showing from ASX healthcare winner
Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
stocks
Is this the $80 billion elephant Warren Buffett has been waiting for?
Morningstar’s Greg Warren says Berkshire may have little choice but to take a hard look at this huge potential acquisition.
stocks
Tesla: Board announces new pay package for CEO Elon Musk
A key provision of the new award is that Musk must remain in a senior leadership position at Tesla.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,028.80 | 106.80 | 1.20% |
| CAC 40 | 7,638.82 | 6.81 | 0.09% |
| DAX 40 | 23,842.60 | 84.91 | 0.36% |
| Dow JONES (US) | 44,173.64 | 42.66 | 0.10% |
| FTSE 100 | 9,153.18 | 24.88 | 0.27% |
| HKSE | 24,902.53 | 169.08 | 0.68% |
| NASDAQ | 21,053.58 | 403.45 | 1.95% |
| Nikkei 225 | 40,549.54 | 258.84 | 0.64% |
| NZX 50 Index | 12,877.04 | 193.00 | 1.52% |
| S&P 500 | 6,329.94 | 91.93 | 1.47% |
| S&P/ASX 200 | 8,770.40 | 106.70 | 1.23% |
| SSE Composite Index | 3,617.60 | 34.29 | 0.96% |